Astemizole in perennial allergic rhinitis with seasonal exacerbations: a placebo-controlled double-blind study.

Abstract

Astemizole is a nonsedative H1-antagonist. It was used in a randomized double-blind, placebo-controlled in-season trial to assess its efficacy in patients with perennial allergic rhinitis showing seasonal exacerbations. By the last (6th) week of the study, the mean overall symptomatology, as rated by a global composite score, was significantly mitigated in the astemizole-treated group (18 patients) compared with their first week's global composite score (P less than .01). No such improvement was observed in the placebo-treated group (18 patients). Side effects were not appreciable throughout this short-term study. We conclude that astemizole is effective in the treatment of patients with perennial allergic rhinitis showing seasonal enhancement of symptoms.

• Authors: A Tanay, I Neuman
• Journal: Annals of allergy (Ann Allergy) Vol. 63 Issue 6 Pt 1 Pg. 493-4 (Dec 1989) ISSN: 0003-4738 [Print] United States
• PMID: 2574549 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Benzimidazoles
• Histamine H1 Antagonists
• Placebos
• Astemizole

Topics

• Astemizole
• Benzimidazoles (therapeutic use)
• Clinical Trials as Topic
• Double-Blind Method
• Histamine H1 Antagonists (therapeutic use)
• Humans
• Placebos
• Rhinitis, Allergic, Perennial (drug therapy)
• Seasons